Publications de Olivier Michielin

Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy

Olivier Michielin, Monia Guidi, Alexandre Wicky, Nadia Terranova, Daniel Abler, Federico Amato

The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model-informed drug development can be used to assess prognostic and predictive clinical factors or biomark ...

2023

Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

Pierre Vogel, Olivier Michielin, Florence Pojer, Somi Reddy Majjigapu, George Coukos

The heme enzyme indoleamine 2,3-dioxygenase 1 (IDO1) plays an essential role in immunity, neuronal function, and aging through catalysis of the rate-limiting step in the kynurenine pathway of tryptophan metabolism. Many IDO1 inhibitors with different chemo ...

AMER CHEMICAL SOC2021

Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu-and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology

Olivier Michielin, Alexandre Wicky, Krisztian Homicsko

We report a case of an uveal melanoma patient with GNAQ p.Gly48Leu who responded to MEK inhibition. At the time of the molecular analysis, the pathogenicity of the mutation was unknown. A tridimensional structural analysis showed that G alpha(q) can adopt ...

2020

The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study

Olivier Michielin, Alexandre Wicky, Krisztian Homicsko, Constantin Tuleasca, Filipe Amândio Brandão Sanches Vong Martins

Background Evidence pointing to a synergistic effect of stereotactic radiosurgery (SRS) with concurrent immunotherapy or targeted therapy in patients with melanoma brain metastases (BM) is increasing. We aimed to analyze the effect on overall survival (OS) ...

SPRINGER2020

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Olivier Michielin, Filipe Amândio Brandão Sanches Vong Martins

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy o ...

NATURE PUBLISHING GROUP2019

MedCo: Enabling Secure and Privacy-Preserving Exploration of Distributed Clinical and Genomic Data

Jean-Pierre Hubaux, Olivier Michielin, Mickaël Misbach, Jean Louis Raisaro, Bryan Alexander Ford, Joao André Gomes de Sá e Sousa, Juan Ramón Troncoso-Pastoriza

The increasing number of health-data breaches is creating a complicated environment for medical-data sharing and, consequently, for medical progress. Therefore, the development of new solutions that can reassure clinical sites by enabling privacy-preservin ...

2019

Lymphatic vessel density is associated with CD8(+) T cell infiltration and immunosuppressive factors in human melanoma

Melody Swartz, Olivier Michielin, Natacha Anne-Sophie Bordry, Manuel Andreas Fankhauser, Esther Danenberg, Maria Anna Sofia Broggi, Timothy Murray

Increased density of tumor-associated lymphatic vessels correlates with poor patient survival in melanoma and other cancers, yet lymphatic drainage is essential for initiating an immune response. Here we asked whether and how lymphatic vessel density (LVD) ...

TAYLOR & FRANCIS INC2018

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma

Olivier Michielin, Elisa Oricchio, Natalya Katanayeva, Maria Christine Donaldson, Elena Battistello, Elie Charles Eugène Dheilly, Giovanni Ciriello, Daniele Tavernari

2018

Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma

Paolo Angelino, Olivier Michielin, Mauro Delorenzi, Etienne Meylan, Jessica Christine Vazquez, Stefania Crippa, Pierre-Benoit Bernard Ancey

Hepatoblastoma is the most common malignant pediatric liver cancer. Histological evaluation of tumor biopsies is used to distinguish among the different subtypes of hepatoblastoma, with fetal and embryonal representing the two main epithelial components. W ...

2017

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma

Melody Swartz, Olivier Michielin, Lambert Charles François Potin, Marcela Rincón-Restrepo, Amanda Waite Lund, Laura Jeanbart, Douglas Hanahan, Sylvie Hauert, Krisztian Homicsko, Natacha Anne-Sophie Bordry, Christopher Claude Giuseppe Tremblay, Manuel Andreas Fankhauser, Maria Anna Sofia Broggi, Elodie Da Costa

In melanoma, vascular endothelial growth factor-C (VEGF-C) expression and consequent lymphangiogenesis correlate with metastasis and poor prognosis. VEGF-C also promotes tumor immunosuppression, suggesting that lymphangiogenesis inhibitors may be clinicall ...

Amer Assoc Advancement Science2017

MedCo: Enabling Privacy-Conscious Exploration of Distributed Clinical and Genomic Data

Jean-Pierre Hubaux, Olivier Michielin, Mickaël Misbach, Jean Louis Raisaro, Bryan Alexander Ford, Joao André Gomes de Sá e Sousa, Juan Ramón Troncoso-Pastoriza

Being able to share large amounts of sensitive clinical and genomic data across several institutions is crucial for precision medicine to scale up. Unfor- tunately, existing solutions only partially address this challenge and are still unable to provide th ...

2017

In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by F-19-Fluorine MRS/MRI

Lothar Helm, Olivier Michielin, Pascal Miéville, Hikari Ananda Infinity Yoshihara

Background F-19-MRI and F-19-MRS can identify specific cell types after in-vitro or in-vivo F-19-labeling. Knowledge on the potential to track in-vitro F-19-labeled immune cells in tumor models by F-19-MRI/MRS is scarce. Aim To study F-19-based MR techniqu ...

Public Library of Science2016

1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)

Pierre Vogel, Olivier Michielin, Somi Reddy Majjigapu, George Coukos

Indoleamine 2,3-dioxygenase 2 (IDO2) is a potential therapeutic target for the treatment of diseases that involve immune escape such as cancer. In contrast to IDO1, only a very limited number of inhibitors have been described for IDO2 due to inherent diffi ...

Pergamon-Elsevier Science Ltd2016

Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Gerardo Turcatti, Marc Chambon, Pierre Vogel, Olivier Michielin, Somi Reddy Majjigapu

Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulator of immune responses and therefore an important therapeutic target for the treatment of diseases that involve pathological immune escape, such as cancer. Here, we describe a robust and sensitive high-t ...

Elsevier France-Editions Scientifiques Medicales Elsevier2014

Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support

Philipp Bucher, Amos Bairoch, Olivier Michielin, Heinz Stockinger, Mauro Delorenzi, Jacques Rougemont, Ioannis Xenarios

The SIB Swiss Institute of Bioinformatics (www.isb-sib.ch) was created in 1998 as an institution to foster excellence in bioinformatics. It is renowned worldwide for its databases and software tools, such as UniProtKB/Swiss-Prot, PROSITE, SWISS-MODEL, STRI ...

Oxford University Press2014

Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition

Pierre Vogel, Olivier Michielin, Somi Reddy Majjigapu

Indoleamine 2,3-dioxygenase 1 (IDO1) is an important therapeutic target treatment of diseases such as cancer that involve pathological immune escape. Starting from the scaffold of our previously discovered IDO1 inhibitor 4-phenyl-1,2,3-triazole, we used co ...

2012

Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function

Olivier Michielin, Nathalie Rufer, Pedro Romero

Protective adaptive immune responses rely on TCR-mediated recognition of Ag-derived peptides presented by self-MHC molecules. However, self-Ag (tumor)-specific TCRs are often of too low affinity to achieve best functionality. To precisely assess the relati ...

American Association of Immunologists ; Oxford University Press2010

Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors

Pierre Vogel, Loay Awad, Olivier Michielin

Indoleamine 2,3-dioxygenase (IDO) is an important therapeutic target for the treatment of diseases such as cancer that involve pathological immune escape. We have used the evolutionary docking algorithm EADock to design new inhibitors of this enzyme. First ...

2010

Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition

Olivier Michielin, Didier Trono, Priscilla Turelli, Bastien Mangeat

Retroelements are important evolutionary forces but can be deleterious if left uncontrolled. Members of the human APOBEC3 family of cytidine deaminases can inhibit a wide range of endogenous, as well as exogenous, retroelements. These enzymes are structura ...

American Society for Microbiology2009

CD8+ Cytotoxic T Lymphocyte Activation by Soluble Major Histocompatibility Complex-Peptide Dimers

Horst Vogel, Jean-Manuel Segura, Bruno Meyer, Olivier Michielin

CD8+ cytotoxic T lymphocyte (CTL) can recognize and kill target cells that express only a few cognate major histocompatibility complex class I-peptide (pMHC) complexes. To better understand the mol. basis of this sensitive recognition process, the authors ...

2005